Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

USP18 inhibits protective immune responses and the intracellular control of Mycobacterium tuberculosis in macrophages.

ABSTRACT: We compared the transcriptome profile of M. tuberculosis-infected murine bone marrow derived macrophages (BMM) treated with either the USP18 small molecule inhibitor BB7 or an inactive control (NC), and uninfected controls as described below. We identified 710 differentially expressed genes (DEGs) between uninfected and Mtb BMM and 243 DEGs comparing Mtb-BB7 vs Mtb BMM, 129 of these DEGs were upregulated. Gene ontology (GO) analysis showed enrichment of pathways related to antiviral responses, innate immune activation and inflammasome signalling when comparing Mtb-BB7 vs Mtb BMM. Conversely, genes associated with stress responses, hypoxia and antioxidant activity were downregulated in Mtb-BB7.

ORGANISM(S): Mus musculus

PROVIDER: GSE320445 | GEO | 2026/03/02

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Methylglyoxal activates the NRF2 pathway and impairs immune responses controlling the growth control of Mycobacterium tuberculosis (Mtb) in macrophages.

Project description:We compared the transcriptome profile of M. tuberculosis-infected murine bone marrow derived macrophages (BMM) treated or not with 200 uM methylglyoxal (MGO) and uninfected controls as described below. We found 3606 differentially expressed genes (DEGs) between uninfected and M. tuberculosis-infected BMM, being approximately half of these upregulated . 1699 DEGs were determined by comparing Mtb-MGO vs M. tuberculosis BMM, with 2/3 of these DEGs downregulated. Genes in the glyoxalate, glutathione and selenocompound metabolic KEEG pathways were increased comparing Mtb-MGO vs M. tuberculosis BMM. Instead genes involved in type I IFN responses, cytokine receptor and chemokine signalling gene ontology clusters (GO) were increased after infection with Mtb as compared to uninfected controls and decreased in Mtb-MGO vs M. tuberculosis BMM.

2024-07-20 | GSE271061 | GEO

USP18-dependent muscle proteome

Project description:USP18 is an interferon type 1 (IFN-1) induced gene that negatively regulates the IFN-1 signalling pathway, which plays a role in many immune related pathologies. Dermatomyositis (DM) is characterised by excessive IFN-1 immune response and muscle degeneration. We found USP18 to be expressed in DM myofibers suggesting a role in muscle cell biology. USP18 depletion induced muscle cell differentiation under nutrient-rich conditions independent of IFN-1 signalling. Downregulation of cell cycle gene network and sarcomeric protein networks, and dysregulation of myogenic (co-)transcription regulators were found in USP18-depleted differentiated cells. Sarcomeric integrity of USP18-depleted cells deteriorated during muscle cell maturation. Our results revealed USP18 as a critical regulator at the intersection between proliferation and differentiation as well as during the maturation of muscle cells. We suggest that a USP18 IFN-1-independent pathway may contribute to muscle regeneration in muscle pathologies.

2023-05-10 | PXD032406 | Pride

USP18-mediated NCOA4 deISGylation and ferroptosis inhibition drives targeted therapy resistance in hepatocellular carcinoma

Project description:To elucidate the principal downstream mediator responsible for USP18-mediated Sorafenib resistance in HCC, we conducted cluster analysis on the differential protein expression based on the whole-proteome analysis of HepG2 cells with or without overexpression of USP18 (HepG2-USP18-OE vs. HepG2-Ctrl), we identified 47 commonly downregulated proteins and 31 upregulated proteins .

2023-12-17 | PXD047888 |

USP18 is an essential regulator of muscle cell differentiation and maturation

2022-03-23 | GSE198794 | GEO

USP18 interactor and PTM mass spectrometry

Project description:The ubiquitin-like protein ISG15 is activated in response to type 1 interferons and its conjugation to proteins regulates the response to bacterial and viral infection. Its subsequent deconjugation, by a single human enzyme, USP18, critically controls interferon signaling and the defense against pathogens. Accordingly, human mutations in USP18 give rise to interferonopathies. However, the molecular determinants underlying USP18 specificity for ISG15 remain elusive. We have identified key mechanisms that underlie the specificity of USP18 towards ISG15, by taking advantage of USP18’s largely unstudied human paralog USP41. Remarkably, we show that USP41 completely lacks the ability to perform deISGylation, despite possessing a catalytic domain that is 97% identical to that of USP18. Using a variety of in vitro and in vivo assays, we performed a comparative analysis to reveal new mechanisms of deISGylation. We define a short, conserved stretch of amino acids, that we term the TAIL motif, as well as a conserved leucine residue in the catalytic domain, which are necessary for deISGylation. Structural analysis revealed that these residues contact ISG15 and are conserved between USP18 and PLpro from SARS-Cov2, underlining their importance in ISG15 specification. Finally, while little is known about USP41, we found that it can bind and negatively regulate FAT10, a poorly studied Ubl which is also involved in the interferon response. While a FAT10 deconjugating enzyme has long been postulated, no such enzyme has ever been described.

2025-07-14 | PXD058618 | Pride

Single-cell transcriptomic analysis of tumor-infiltrated immune cells from myeloid-specific Usp18 knockout mice

Project description:Ubiquitin specific peptidase 18 (USP18) inhibits type I interferon response and mediates ISG15-deconjugation. Here, we examined the role of USP18 in myeloid-linage cells in tumor development. B16F10 melanoma grown in control or myeloid-specific Usp18 knockout mice were analyzed. Single-cell transcriptomic analysis revealed that the profile of tumor-infiltrated immune cells were altered with Usp18 deletion. We observed that increase in M1-polarized macrophages and decrease in myeloid-derived suppressor cells, resulting enhanced anti-tumor microenvironment in Usp18 conditional knockout mice.

2024-02-14 | GSE173705 | GEO

Deep analysis of the USP18-dependent ISGylome and proteome unveils important roles for USP18 in tumour cell antigenicity and radiosensitivity

Project description:The deubiquitylating enzyme USP18 is a major negative regulator of the interferon (IFN) signalling cascade. IFN pathways contribute to resistance to conventional chemotherapy, radiotherapy, and immunotherapy and are often upregulated in certain tumours, including breast, lung, and colon tumours. USP18 is the predominant human protease that cleaves interferon-stimulated gene ISG15, a ubiquitin-like protein tightly regulated in the context of innate immunity, from its modified substrate proteins in vivo. In this study, using advanced proteomic techniques, we have expanded the USP18-dependent ISGylome and proteome in a chronic myeloid leukaemia (CML)-derived cell line (HAP1) treated with type I IFN. Novel ISGylation targets were characterised that modulate the sensing of innate ligands, antigen presentation and secretion of cytokines. Consequently, CML USP18-deficient cells are more antigenic, driving increased activation of cytotoxic T lymphocytes (CTLs) and are more susceptible to irradiation. Our results suggest USP18 as a pharmacological target in cancer immunotherapy and radiotherapy.

2022-02-15 | PXD018299 | Pride

Microarray analysis to evaluate the function of USP18 in the mouse CNS

Project description:Microglia are tissue macrophages of the central nervous system (CNS) that control tissue homeostasis, and as such they are crucially important for organ integrity. Microglia dysregulation is thought to be causal for a group of neuropsychiatric, neurodegenerative and neuroinflammatory diseases, called ‚Äòmicrogliopathies‚Äô. However, how the intracellular stimulation machinery in microglia is controlled is poorly understood. By using expression studies, we identified the ubiquitin-specific protease (Usp) 18 in white matter microglia that essentially contributes to microglial quiescence under homeostatic conditions. We further found that microglial Usp18 negatively regulated the activation of STAT1 and concomitant induction of interferon-induced genes thereby disabling the termination of IFN signalling. Unexpectedly, the Usp18-mediated feedback loop was independent from the catalytic domain of the protease but instead required the interacting region of Ifnar2. Additionally, the absence of Ifnar1 completely rescued microglial activation indicating a tonic IFN signal mediated by receptor interactions under non-diseased conditions. Finally, conditional depletion of Usp18 only in myeloid cells significantly enhanced the disease burden in a mouse model of CNS autoimmunity, increased axonal and myelin damage and determined the spatial distributions of CNS lesions that shared the same STAT1 signature as myeloid cells found in active multiple sclerosis (MS) lesions. These results identify Usp18 as novel negative regulator of microglia activation, demonstrate a protective role of the IFNAR pathway for microglia and establish Usp18 as potential therapeutic target for the treatment of MS. Brain lysate of adult WT, USP18ko, IFNAR1ko and USP18ko:IFNARko mice were analyzed

2015-04-20 | E-GEOD-61499 | biostudies-arrayexpress

The transcriptomic analysis for Usp18 heterozygous depletion in established AML1/ETO 9a leukemia mouse model [AE9a_scRNA-seq]

Project description:Usp18 is a potent negative reguator of type I IFN signaling. However, it is not well characterized how Usp18 affects IFN stimulated genes (ISGs) induction in AML in mouse model. Here, we analyzed the transcriptomic data when combined with heterozygous depletion of USP18, which phenotypicaly reduce AE9a leukemia progression.

2022-11-09 | GSE165425 | GEO

The transcriptomic analysis for Usp18 heterozygous depletion in established AML1/ETO 9a leukemia mouse model [AE9a_RNA-seq]

2022-11-09 | GSE165424 | GEO